Financial Analysis: Lineage Cell Therapeutics Inc (LCTX)’s Ratios Unveil Key Insights

Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.

As of close of business last night, Lineage Cell Therapeutics Inc’s stock clocked out at $1.09, down -6.84% from its previous closing price of $1.17. In other words, the price has decreased by -$6.84 from its previous closing price. On the day, 0.87 million shares were traded. LCTX stock price reached its highest trading level at $1.17 during the session, while it also had its lowest trading level at $1.07.

Ratios:

To gain a deeper understanding of LCTX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.71 and its Current Ratio is at 2.71. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on November 02, 2022, initiated with a Outperform rating and assigned the stock a target price of $5.

On June 14, 2022, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $4.

On August 19, 2021, Noble Capital Markets started tracking the stock assigning a Outperform rating and target price of $8.Noble Capital Markets initiated its Outperform rating on August 19, 2021, with a $8 target price.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 08 ’24 when BAILEY DON M bought 96,155 shares for $1.04 per share. The transaction valued at 100,001 led to the insider holds 158,801 shares of the business.

BROADWOOD PARTNERS, L.P. bought 6,730,770 shares of LCTX for $7,000,001 on Feb 06 ’24. The Director now owns 41,666,255 shares after completing the transaction at $1.04 per share. On Dec 29 ’23, another insider, Jayasuriya Anula, who serves as the Director of the company, bought 10,000 shares for $1.09 each. As a result, the insider paid 10,900 and bolstered with 10,000 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LCTX now has a Market Capitalization of 205789824 and an Enterprise Value of 164010976. For the stock, the TTM Price-to-Sale (P/S) ratio is 25.72 while its Price-to-Book (P/B) ratio in mrq is 2.84. Its current Enterprise Value per Revenue stands at 20.494 whereas that against EBITDA is -7.99.

Stock Price History:

The Beta on a monthly basis for LCTX is 1.35, which has changed by -0.19852942 over the last 52 weeks, in comparison to a change of 0.2704494 over the same period for the S&P500. Over the past 52 weeks, LCTX has reached a high of $1.61, while it has fallen to a 52-week low of $0.84. The 50-Day Moving Average of the stock is -12.04%, while the 200-Day Moving Average is calculated to be -8.15%.

Shares Statistics:

It appears that LCTX traded 963.20K shares on average per day over the past three months and 1219870 shares per day over the past ten days. A total of 188.80M shares are outstanding, with a floating share count of 187.75M. Insiders hold about 0.55% of the company’s shares, while institutions hold 48.42% stake in the company. Shares short for LCTX as of 1714435200 were 10901781 with a Short Ratio of 11.32, compared to 1711584000 on 10397492. Therefore, it implies a Short% of Shares Outstanding of 10901781 and a Short% of Float of 7.4499995.

Earnings Estimates

Investors are keenly observing as 6.0 analysts analyze and rate the current performance of Lineage Cell Therapeutics Inc (LCTX) in the stock market.On average, analysts expect EPS of -$0.04 for the current quarter, with a high estimate of -$0.03 and a low estimate of -$0.05, while EPS last year was -$0.03. The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.03 and low estimates of -$0.06.

Analysts are recommending an EPS of between -$0.01 and -$0.22 for the fiscal current year, implying an average EPS of -$0.11. EPS for the following year is -$0.12, with 5.0 analysts recommending between -$0.03 and -$0.21.

Revenue Estimates

Based on 5 analysts’ estimates, the company’s revenue will be $16.98M in the next fiscal year. The high estimate is $50M and the low estimate is $1.83M.

Most Popular

[the_ad id="945"]